Sanofi's Immunology Initiatives and Collaborations

We’re partnering to bring cutting-edge technologies and assets to patients suffering from immuno-inflammatory conditions.

Beyond Dupixent®

We’re building on the success of Dupixent® in atopic dermatitis and asthma, developing new solutions for people with debilitating immuno-dermatological, rheumatic, respiratory, and gastrointestinal diseases.

Automatisation lab. mRNA equipment  - Marcy l'Etoile, France
Automatisation lab. mRNA equipment - Marcy l'Etoile, France

Scaling up Innovation

We partner with companies that bring cutting-edge technologies and transformative assets in immuno-inflammation. We bring expertise in biological pathways, research-enabling technologies, proven precision-medicine approaches to clinical development, and robust commercial organization. 

Partnering Success Stories


This global collaboration produced Dupixent®, a novel biologic approved for atopic dermatitis, severe asthma, and eosinophilic esophagitis, and in development for a range of additional potential indications.


In partnership with Kymera, we develop and commercialize first-in-class protein degrader therapies that target IRAK4 in patients with immuno-inflammatory diseases.


We’re working on a CD40L monoclonal antibody (INX-021) initially developed by ImmuNext, as a treatment for autoimmune diseases including lupus and multiple sclerosis. 

Your Partnering Leads in Immunology

For more information, contact our Business development team

Mark Dowling

Mark Dowling

Head of External Innovation, Immunology

Ulrich Wendt

Ulrich Wendt

Global Head of Business Development, Immunology